Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Among patients with newly diagnosed chronic-phase CML who are receiving imatinib, the long-term outcome is more favorable for those in whom a complete cytogenetic response is achieved at 12 months ...

This review discusses the development and uses of imatinib mesylate, a protein tyrosine kinase inhibitor useful in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors ...

New research suggests that the mechanism of action of imatinib also results in cardiotoxicity and might explain reports of cardiac failure.

Learn about side effects, uses, cost, and more for imatinib oral tablets. This is a generic drug that treats certain types of cancer in adults and some children.

Imatinib has been joined by several more tyrosine kinase inhibitors, including the second-generation agents nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, Bristol-Myers Squibb).

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial ...

With imatinib’s recent IND clearance, Tenax expects to start its Phase III registrational study early next year following the active PK study, with trial conclusion and results expected in 4Q:21.

Imatinib remains the first-line standard for advanced GIST with imatinib-sensitive mutations. Whether treatment interruption affects resistance to imatinib or survival remains unclear, Blay and ...

Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a randomized trial showed ...

Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months.